St. Johns Wort (Hypericin).

St John's wort constituents slow the reuptake of serotonin while 5-HTP raises how much serotonin is made. Together they load the same synaptic pool from both the supply side and the clearance side, which is why the pairing is flagged rather than recommended.

5-HTP crosses into the brain and is decarboxylated straight to serotonin, while the herb reduces its clearance from the synapse. The two additions to one pathway compound each other.

Tryptophan is the upstream substrate for serotonin synthesis and the herb slows serotonin clearance. Raising synthesis and lowering clearance at once acts on the same pathway twice.

The amino acid feeds serotonin production while hyperforin-rich extract reduces reuptake. The combined effect on serotonergic tone is greater than either alone.

SAM-e drives methylation steps in monoamine synthesis and turnover, and the herb raises monoamine availability in the synapse. Both act on the same neurotransmitter pool.

Saffron constituents are described as acting on serotonin reuptake, the same handle the herb uses. Overlapping mechanisms mean the effect on serotonergic tone is not independent.

St John's wort induces the CYP enzymes and intestinal efflux pump that clear many co-ingested compounds, so melatonin exposure can fall. Melatonin is also made downstream of serotonin, putting both on one axis.

Rhodiola salidrosides are described as slowing monoamine breakdown while the herb slows reuptake. Stacking two monoamine-sparing mechanisms is additive on the same pool.

St John's wort is a strong inducer of CYP3A4 and P-glycoprotein while berberine inhibits them, so each changes how much of the other reaches circulation. Exposure of anything else in the formula that uses those routes also shifts.

Induction of intestinal efflux and CYP3A4 by the herb speeds removal of co-dosed polyphenols that already absorb poorly. The curcumin dose that reaches circulation can fall as a result.

Piperine inhibits CYP3A4 and P-glycoprotein while the herb induces both, so the two pull the absorption of everything else in the formula in opposite directions. Neither the piperine boost nor the baseline exposure is predictable in that combination.

Aromatic L-amino acid decarboxylase requires pyridoxal-5-phosphate to convert 5-HTP to serotonin and L-DOPA to dopamine. St John's wort constituents act on monoamine handling downstream of that step, so adequate B6 status is a precondition rather than an additive effect. This is settled biochemistry, not a tested product pairing.

Folate in its reduced form supports tetrahydrobiopterin availability, the cofactor for tryptophan and tyrosine hydroxylase, which set the rate of serotonin and catecholamine synthesis. St John's wort acts on the reuptake and receptor side of the same system. Supplying substrate-side support alongside a reuptake-side botanical is mechanistically coherent.

B12 is the cofactor for methionine synthase, and without it methylfolate is trapped and the methyl supply for downstream methylation stalls. Any folate-based support of monoamine synthesis therefore depends on B12 status. The relationship is textbook, and it is a prerequisite rather than a synergy in the marketing sense.

Tyrosine is hydroxylated to L-DOPA and then decarboxylated to dopamine, supplying substrate to the catecholamine branch. Hypericum constituents inhibit synaptosomal reuptake of noradrenaline and dopamine in laboratory preparations, which acts on the same transmitters from the other end. No human study of the pair was located.

Phenylalanine hydroxylase converts phenylalanine to tyrosine, one step further back on the same chain. The pairing rationale is identical to tyrosine and adds nothing beyond it in people with normal hydroxylase activity. Read it as substrate supply, not as an effect.

Hyperforin is a potent agonist of the pregnane X receptor, and PXR activation induces CYP24A1 and CYP3A4, both of which catabolise vitamin D metabolites. Sustained St John's wort intake can therefore lower circulating 25-hydroxyvitamin D. This is a pharmacokinetic interaction with a well-described receptor mechanism, not a claim about clinical status.

Hyperforin-driven induction of intestinal P-glycoprotein and CYP3A4 lowers the systemic exposure of many lipophilic substrates taken alongside it. CoQ10 is highly lipophilic and absorbed through the same intestinal route. The direction is reduced exposure, though the size of the effect for CoQ10 specifically has not been measured.

Quercetin inhibits P-glycoprotein in laboratory systems, while hyperforin induces it over days of repeated exposure. Inhibition is fast and induction is slow, so the net effect on a co-administered substrate depends on how long the pair has been taken. This is a genuine two-directional interaction rather than an additive one.

Silymarin constituents inhibit several CYP isoforms and UGT enzymes in vitro, while St John's wort induces CYP3A4 through PXR. Combining them puts opposing pressures on the same clearance machinery. The net result on any third compound is not predictable from either herb alone.

EGCG is both a substrate and a modulator of intestinal efflux transporters, the same transporters hyperforin induces. Taken together over weeks the induction side tends to dominate. Treatment of this as a formulation caution is appropriate; expect altered exposure rather than a clean additive effect.

Ginkgo acts largely on microvascular flow and platelet-activating factor, while hypericum constituents act on monoamine reuptake and receptor density. The mechanisms are separate, so the pairing is complementary rather than duplicative. Both carry their own interaction profiles that stack when combined.

Bacosides are associated with cholinergic and antioxidant activity in preclinical work, a different axis from hypericum's monoaminergic one. Formulators pair them for that separation. No combination study was located and the confidence stays low for that reason.

Withanolides are described as acting on the hypothalamic-pituitary-adrenal axis, while hypericum acts on monoamine handling. The two are not redundant. This is a formulation rationale with preclinical support on each side and no combination data.

Lemon balm rosmarinic acid inhibits GABA transaminase in laboratory models, raising GABA availability, which is a different route from monoamine reuptake. Both appear in European herbal blends together. Combined sedative load is the practical consideration.

Valerian acts on GABAergic signalling and adenosine receptors, while hypericum works on monoamines. Fixed combinations of the two have been marketed in Europe for decades. The additive direction is on sedation, which is what to watch when both are dosed in the evening.

Passionflower flavonoids including chrysin show GABA-A activity in preclinical models, a separate target from hypericum's. Blends combine them for breadth. Expect additive sedation and nothing more specific than that from the available evidence.

Magnesium is required by hundreds of ATP-dependent enzymes, including steps in catecholamine synthesis and the methylation reactions that support it, and it modulates NMDA receptor activity. Its role beside a monoaminergic botanical is permissive. This is textbook cofactor biochemistry, not a tested combination.

Zinc is a structural component of many enzymes and modulates NMDA and GABA-A receptor function directly at synaptic concentrations. Adequate status is a background requirement for the systems hypericum acts on. Read this as a prerequisite rather than an effect of the pair.

The polyphenol and tannin fraction of hypericum preparations binds non-heme iron in the gut lumen and lowers its absorption. Separating the two by a couple of hours removes most of the interaction. Iron is also required by tryptophan hydroxylase, so the competition sits upstream of the pathway hypericum acts on.

EPA and DHA incorporate into neuronal membrane phospholipids and influence receptor fluidity and eicosanoid signalling, which is structural rather than transmitter-level. Hypericum acts on reuptake and receptor expression. The two are non-overlapping, which is the rationale for combining them.